144 related articles for article (PubMed ID: 36579470)
1. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
McDonald AM; DeMora L; Yang ES; Hoyle JM; Lenzie A; Williams GR; Michalski JM; Yee D; Bahary JP; Den RB; Roach M; Dess R; Mishra MV; Valicenti RK; Lau HY; Marcrom SR; Souhami L; Mendez LC; Chen Y; Doncals DE; Pugh SL; Feng FY; Sandler HM
Cancer; 2023 Mar; 129(5):685-696. PubMed ID: 36579470
[TBL] [Abstract][Full Text] [Related]
2. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
[TBL] [Abstract][Full Text] [Related]
3. CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men with Prostate Cancer.
McDonald AM; Swain TA; Mayhew DL; Cardan RA; Baker CB; Harris DM; Yang ES; Fiveash JB
Radiology; 2017 Feb; 282(2):475-483. PubMed ID: 27598538
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
6. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
Jackson WC; Tang M; Schipper MJ; Sandler HM; Zumsteg ZS; Efstathiou JA; Shipley WU; Seiferheld W; Lukka HR; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Hall WA; Dess RT; Lovett RD; Balogh AG; Feng FY; Spratt DE
J Clin Oncol; 2022 Sep; 40(27):3172-3179. PubMed ID: 35737923
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline.
Vogel MME; Düsberg M; Stöhrer L; Dewes S; Sage EK; Borm KJ; Gschwend JE; Eiber M; Combs SE; Schiller K
Eur Urol Oncol; 2022 Dec; 5(6):668-676. PubMed ID: 36280446
[TBL] [Abstract][Full Text] [Related]
8. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
9. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU; Pugh SL; Sandler HM; Chetner MP; Amin MB; Bruner DW; Zietman AL; Den RB; Leibenhaut MH; Longo JM; Bahary JP; Rosenthal SA; Souhami L; Michalski JM; Hartford AC; Amin PP; Roach M; Yee D; Efstathiou JA; Rodgers JP; Feng FY; Shipley WU
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):294-303. PubMed ID: 34481017
[TBL] [Abstract][Full Text] [Related]
10. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
Hallemeier CL; Zhang P; Pisansky TM; Hanks GE; McGowan DG; Roach M; Zeitzer KL; Firat SY; Husain SM; D'Souza DP; Souhami L; Parliament MB; Rosenthal SA; Lukka HR; Rotman M; Horwitz EM; Miles EF; Paulus R; Sandler HM
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1057-1065. PubMed ID: 30959123
[TBL] [Abstract][Full Text] [Related]
11. Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415.
Bai J; Pugh SL; Eldridge R; Yeager KA; Zhang Q; Lee WR; Shah AB; Dayes IS; D'Souza DP; Michalski JM; Efstathiou JA; Longo JM; Pisansky TM; Maier JM; Faria SL; Desai AB; Seaward SA; Sandler HM; Cooley ME; Bruner DW
Int J Radiat Oncol Biol Phys; 2023 May; 116(1):39-49. PubMed ID: 36736921
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
Nguyen PL; Huang HR; Spratt DE; Davicioni E; Sandler HM; Shipley WU; Efstathiou JA; Simko JP; Pollack A; Dicker AP; Roach M; Rosenthal SA; Zeitzer KL; Mendez LC; Hartford AC; Hall WA; Desai AB; Rabinovitch RA; Peters CA; Rodgers JP; Tran P; Feng FY
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):521-529. PubMed ID: 36596347
[TBL] [Abstract][Full Text] [Related]
13. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
[TBL] [Abstract][Full Text] [Related]
14. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
16. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
17. Psoas and paraspinous muscle index as a predictor of mortality in African American men with type 2 diabetes mellitus.
Murea M; Lenchik L; Register TC; Russell GB; Xu J; Smith SC; Bowden DW; Divers J; Freedman BI
J Diabetes Complications; 2018 Jun; 32(6):558-564. PubMed ID: 29627372
[TBL] [Abstract][Full Text] [Related]
18. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
Ross AE; Zhang J; Huang HC; Yamashita R; Keim-Malpass J; Simko JP; DeVries S; Morgan TM; Souhami L; Dobelbower MC; McGinnis LS; Jones CU; Dess RT; Zeitzer KL; Choi K; Hartford AC; Michalski JM; Raben A; Gomella LG; Sartor AO; Rosenthal SA; Sandler HM; Spratt DE; Pugh SL; Mohamad O; Esteva A; Chen E; Schaeffer EM; Tran PT; Feng FY
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38302323
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?
Nieder C; Nestle U; Motaref B; Walter K; Niewald M; Schnabel K
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):297-302. PubMed ID: 10661335
[TBL] [Abstract][Full Text] [Related]
20. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Gittleman H; Lim D; Kattan MW; Chakravarti A; Gilbert MR; Lassman AB; Lo SS; Machtay M; Sloan AE; Sulman EP; Tian D; Vogelbaum MA; Wang TJC; Penas-Prado M; Youssef E; Blumenthal DT; Zhang P; Mehta MP; Barnholtz-Sloan JS
Neuro Oncol; 2017 May; 19(5):669-677. PubMed ID: 28453749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
